Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 585-588, 2023.
Article
в Zh
| WPRIM
| ID: wpr-982099
Ответственная библиотека:
WPRO
ABSTRACT
The treatment of chronic myeloid leukemia (CML) was revolutionized with the advent of the first-generation tyrosine kinase inhibitors (TKIs), but drug resistance developed during treatment, leading to the development of the second-generation (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKI. Compared with previous treatment regimens, specific TKI can significantly improve the response rate, overall survival rate and prognosis of CML. Only a few patients with BCR-ABL mutation are insensitive to the second-generation TKIs, so it is suggested to select the second-generation TKIs for patients with specific mutations. For patients with other mutations and without mutations, the second-generation TKI should be selected according to the patient's medical history, while the third-generation TKIs should be selected for mutations that are insensitive to the second-generation TKIs, such as T315I mutation that is sensitive to ponatinib. Due to different BCR-ABL mutations in patients with different sensitivity to the second and third-generation TKIs, this paper will review the latest research progress of the efficacy of the second and third-generation TKIs in CML patients with BCR-ABL mutations.
Key words
Полный текст:
1
База данных:
WPRIM
Основная тема:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Fusion Proteins, bcr-abl
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
Dasatinib
/
Mutation
/
Antineoplastic Agents
Пределы темы:
Humans
Язык:
Zh
Журнал:
Journal of Experimental Hematology
Год:
2023
Тип:
Article